Core Viewpoint - Cell therapy presents a promising method for treating liver diseases, with the challenge of obtaining sufficient safe and functional liver cells for transplantation and treatment [3]. Group 1: Research Findings - A research team from the Navy Medical University and Shanghai Jiao Tong University published a paper on large-scale manufacturing of human gallbladder epithelial cells (hGBEC) and derived hepatocytes, which was selected as a cover paper in Trends in Biotechnology [4]. - The team established a component-defined, Matrigel-free culture system for hGBEC, enabling large-scale production under GMP conditions, and successfully generated functional hepatocytes that demonstrated typical liver functions [4][8]. - The production process can yield at least 10^11 cells from a single donor, sufficient to treat multiple adult patients with liver failure, ensuring quality control and biosafety [8]. Group 2: Clinical Implications - The generated hepatocytes exhibit typical liver functions, including albumin secretion, urea production, and drug metabolism, and can be used for drug toxicity testing [8]. - In vivo transplantation of these functional hepatocytes successfully rescued mice with liver failure, indicating potential clinical applications for liver disease treatment [8][10]. - The large-scale and convenient production strategy of hGBEC serves as a biological resource for clinical applications and provides valuable models for liver disease research [10].